nodes	percent_of_prediction	percent_of_DWPC	metapath
Sunitinib—pancreatic cancer—esophageal cancer	0.366	1	CtDrD
Sunitinib—CSNK1A1—esophageal cancer	0.11	0.288	CbGaD
Sunitinib—SBK1—esophageal cancer	0.11	0.288	CbGaD
Sunitinib—MAP3K3—esophageal cancer	0.076	0.199	CbGaD
Sunitinib—CHEK2—esophageal cancer	0.0428	0.112	CbGaD
Sunitinib—KDR—esophageal cancer	0.0239	0.0627	CbGaD
Sunitinib—ABCC2—esophageal cancer	0.0141	0.0371	CbGaD
Sunitinib—ABCC2—Carboplatin—esophageal cancer	0.00727	0.167	CbGbCtD
Sunitinib—ABCC4—Methotrexate—esophageal cancer	0.00678	0.156	CbGbCtD
Sunitinib—ABCG2—Carboplatin—esophageal cancer	0.00657	0.151	CbGbCtD
Sunitinib—ABCC2—Cisplatin—esophageal cancer	0.00621	0.143	CbGbCtD
Sunitinib—ABCG2—Cisplatin—esophageal cancer	0.00561	0.129	CbGbCtD
Sunitinib—ABCB1—esophageal cancer	0.0052	0.0136	CbGaD
Sunitinib—ABCC2—Methotrexate—esophageal cancer	0.00403	0.0928	CbGbCtD
Sunitinib—ABCG2—Methotrexate—esophageal cancer	0.00364	0.0839	CbGbCtD
Sunitinib—ABCB1—Cisplatin—esophageal cancer	0.00202	0.0466	CbGbCtD
Sunitinib—ABCB1—Methotrexate—esophageal cancer	0.00131	0.0302	CbGbCtD
Sunitinib—FGFR2—epithelium—esophageal cancer	0.000131	0.00217	CbGeAlD
Sunitinib—PDGFRB—neck—esophageal cancer	0.00013	0.00217	CbGeAlD
Sunitinib—JAK2—epithelium—esophageal cancer	0.00013	0.00216	CbGeAlD
Sunitinib—SLK—bronchus—esophageal cancer	0.00013	0.00216	CbGeAlD
Sunitinib—PAK3—lymph node—esophageal cancer	0.000129	0.00214	CbGeAlD
Sunitinib—CDK16—lymph node—esophageal cancer	0.000129	0.00214	CbGeAlD
Sunitinib—LATS2—lymph node—esophageal cancer	0.000129	0.00214	CbGeAlD
Sunitinib—STK16—lung—esophageal cancer	0.000129	0.00214	CbGeAlD
Sunitinib—MAP3K7—trachea—esophageal cancer	0.000129	0.00214	CbGeAlD
Sunitinib—HIPK2—lung—esophageal cancer	0.000128	0.00213	CbGeAlD
Sunitinib—HIPK3—lung—esophageal cancer	0.000128	0.00213	CbGeAlD
Sunitinib—ALK—lung—esophageal cancer	0.000128	0.00213	CbGeAlD
Sunitinib—JAK2—bronchus—esophageal cancer	0.000128	0.00213	CbGeAlD
Sunitinib—MAP2K1—digestive system—esophageal cancer	0.000128	0.00213	CbGeAlD
Sunitinib—TBK1—trachea—esophageal cancer	0.000127	0.00211	CbGeAlD
Sunitinib—RPS6KA5—lymph node—esophageal cancer	0.000127	0.00211	CbGeAlD
Sunitinib—TNK1—lung—esophageal cancer	0.000127	0.00211	CbGeAlD
Sunitinib—RIOK2—lung—esophageal cancer	0.000127	0.00211	CbGeAlD
Sunitinib—TYK2—trachea—esophageal cancer	0.000126	0.0021	CbGeAlD
Sunitinib—FYN—bronchus—esophageal cancer	0.000126	0.0021	CbGeAlD
Sunitinib—CSNK1A1—digestive system—esophageal cancer	0.000126	0.0021	CbGeAlD
Sunitinib—FGFR2—smooth muscle tissue—esophageal cancer	0.000126	0.00209	CbGeAlD
Sunitinib—MAP4K1—lung—esophageal cancer	0.000126	0.00209	CbGeAlD
Sunitinib—MAP3K19—lung—esophageal cancer	0.000126	0.00209	CbGeAlD
Sunitinib—CLK1—digestive system—esophageal cancer	0.000125	0.00208	CbGeAlD
Sunitinib—JAK2—smooth muscle tissue—esophageal cancer	0.000125	0.00208	CbGeAlD
Sunitinib—FYN—smooth muscle tissue—esophageal cancer	0.000123	0.00205	CbGeAlD
Sunitinib—MAP4K5—bronchus—esophageal cancer	0.000123	0.00205	CbGeAlD
Sunitinib—MAP3K3—bronchus—esophageal cancer	0.000123	0.00205	CbGeAlD
Sunitinib—DAPK3—lung—esophageal cancer	0.000123	0.00205	CbGeAlD
Sunitinib—CAMK2G—digestive system—esophageal cancer	0.000123	0.00205	CbGeAlD
Sunitinib—CLK4—lymph node—esophageal cancer	0.000122	0.00203	CbGeAlD
Sunitinib—RPS6KB1—trachea—esophageal cancer	0.000122	0.00203	CbGeAlD
Sunitinib—CLK2—lung—esophageal cancer	0.000122	0.00203	CbGeAlD
Sunitinib—MAP4K2—lung—esophageal cancer	0.000121	0.00202	CbGeAlD
Sunitinib—AXL—trachea—esophageal cancer	0.000121	0.00201	CbGeAlD
Sunitinib—FLT1—epithelium—esophageal cancer	0.000121	0.00201	CbGeAlD
Sunitinib—ITK—lymph node—esophageal cancer	0.000121	0.00201	CbGeAlD
Sunitinib—SBK1—lymph node—esophageal cancer	0.000121	0.00201	CbGeAlD
Sunitinib—MAP4K5—smooth muscle tissue—esophageal cancer	0.000121	0.00201	CbGeAlD
Sunitinib—PRKAA1—digestive system—esophageal cancer	0.00012	0.002	CbGeAlD
Sunitinib—STK3—lung—esophageal cancer	0.00012	0.00199	CbGeAlD
Sunitinib—BLK—lymph node—esophageal cancer	0.00012	0.00199	CbGeAlD
Sunitinib—FLT1—bronchus—esophageal cancer	0.000119	0.00198	CbGeAlD
Sunitinib—PTK2B—digestive system—esophageal cancer	0.000119	0.00198	CbGeAlD
Sunitinib—ROCK1—lung—esophageal cancer	0.000118	0.00197	CbGeAlD
Sunitinib—DAPK1—lymph node—esophageal cancer	0.000118	0.00196	CbGeAlD
Sunitinib—PHKG1—lymph node—esophageal cancer	0.000118	0.00196	CbGeAlD
Sunitinib—EPHB6—bronchus—esophageal cancer	0.000118	0.00196	CbGeAlD
Sunitinib—Mouth ulceration—Capecitabine—esophageal cancer	0.000118	0.00218	CcSEcCtD
Sunitinib—CSNK1E—digestive system—esophageal cancer	0.000117	0.00194	CbGeAlD
Sunitinib—Hypokalaemia—Cisplatin—esophageal cancer	0.000117	0.00216	CcSEcCtD
Sunitinib—FLT1—smooth muscle tissue—esophageal cancer	0.000117	0.00194	CbGeAlD
Sunitinib—SLK—trachea—esophageal cancer	0.000117	0.00194	CbGeAlD
Sunitinib—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.000116	0.00214	CcSEcCtD
Sunitinib—DYRK1A—lung—esophageal cancer	0.000115	0.00192	CbGeAlD
Sunitinib—JAK2—trachea—esophageal cancer	0.000115	0.00191	CbGeAlD
Sunitinib—Nasopharyngitis—Cisplatin—esophageal cancer	0.000115	0.00212	CcSEcCtD
Sunitinib—BRD4—lymph node—esophageal cancer	0.000114	0.0019	CbGeAlD
Sunitinib—STK11—lymph node—esophageal cancer	0.000114	0.0019	CbGeAlD
Sunitinib—YES1—bronchus—esophageal cancer	0.000114	0.00189	CbGeAlD
Sunitinib—FYN—trachea—esophageal cancer	0.000113	0.00188	CbGeAlD
Sunitinib—RPS6KA1—lymph node—esophageal cancer	0.000113	0.00188	CbGeAlD
Sunitinib—RIOK1—lymph node—esophageal cancer	0.000113	0.00188	CbGeAlD
Sunitinib—Sepsis—Capecitabine—esophageal cancer	0.000113	0.00209	CcSEcCtD
Sunitinib—STK10—bronchus—esophageal cancer	0.000113	0.00188	CbGeAlD
Sunitinib—MERTK—lung—esophageal cancer	0.000113	0.00187	CbGeAlD
Sunitinib—ULK3—digestive system—esophageal cancer	0.000113	0.00187	CbGeAlD
Sunitinib—MAP2K2—digestive system—esophageal cancer	0.000113	0.00187	CbGeAlD
Sunitinib—TAOK3—bronchus—esophageal cancer	0.000112	0.00187	CbGeAlD
Sunitinib—YES1—smooth muscle tissue—esophageal cancer	0.000111	0.00185	CbGeAlD
Sunitinib—TNIK—lymph node—esophageal cancer	0.000111	0.00185	CbGeAlD
Sunitinib—MARK2—lymph node—esophageal cancer	0.000111	0.00185	CbGeAlD
Sunitinib—MAP3K3—trachea—esophageal cancer	0.000111	0.00184	CbGeAlD
Sunitinib—MAP4K5—trachea—esophageal cancer	0.000111	0.00184	CbGeAlD
Sunitinib—MAP4K4—lung—esophageal cancer	0.000111	0.00184	CbGeAlD
Sunitinib—Proteinuria—Methotrexate—esophageal cancer	0.00011	0.00204	CcSEcCtD
Sunitinib—SGK3—lymph node—esophageal cancer	0.00011	0.00183	CbGeAlD
Sunitinib—NUAK2—lung—esophageal cancer	0.00011	0.00182	CbGeAlD
Sunitinib—TBK1—digestive system—esophageal cancer	0.000109	0.00182	CbGeAlD
Sunitinib—PDGFRA—smooth muscle tissue—esophageal cancer	0.000109	0.00182	CbGeAlD
Sunitinib—ICK—lymph node—esophageal cancer	0.000109	0.00181	CbGeAlD
Sunitinib—MAP3K12—lung—esophageal cancer	0.000109	0.00181	CbGeAlD
Sunitinib—FLT3—lung—esophageal cancer	0.000109	0.00181	CbGeAlD
Sunitinib—Protein urine present—Methotrexate—esophageal cancer	0.000109	0.00201	CcSEcCtD
Sunitinib—Blood alkaline phosphatase increased—Capecitabine—esophageal cancer	0.000109	0.00201	CcSEcCtD
Sunitinib—Pancreatitis—Cisplatin—esophageal cancer	0.000109	0.00201	CcSEcCtD
Sunitinib—TYK2—digestive system—esophageal cancer	0.000109	0.00181	CbGeAlD
Sunitinib—Hepatic function abnormal—Capecitabine—esophageal cancer	0.000108	0.002	CcSEcCtD
Sunitinib—RPS6KA3—lung—esophageal cancer	0.000107	0.00179	CbGeAlD
Sunitinib—Skin discolouration—Methotrexate—esophageal cancer	0.000107	0.00198	CcSEcCtD
Sunitinib—FLT1—trachea—esophageal cancer	0.000107	0.00178	CbGeAlD
Sunitinib—MAP2K1—lung—esophageal cancer	0.000107	0.00177	CbGeAlD
Sunitinib—Abdominal discomfort—Cisplatin—esophageal cancer	0.000106	0.00197	CcSEcCtD
Sunitinib—EPHB6—trachea—esophageal cancer	0.000106	0.00176	CbGeAlD
Sunitinib—Pancytopenia—Cisplatin—esophageal cancer	0.000105	0.00195	CcSEcCtD
Sunitinib—CSNK1A1—lung—esophageal cancer	0.000105	0.00175	CbGeAlD
Sunitinib—CHEK2—lymph node—esophageal cancer	0.000105	0.00175	CbGeAlD
Sunitinib—NUAK1—lymph node—esophageal cancer	0.000105	0.00175	CbGeAlD
Sunitinib—Glossitis—Methotrexate—esophageal cancer	0.000105	0.00195	CcSEcCtD
Sunitinib—Hepatic failure—Capecitabine—esophageal cancer	0.000105	0.00195	CcSEcCtD
Sunitinib—RPS6KB1—digestive system—esophageal cancer	0.000105	0.00175	CbGeAlD
Sunitinib—CLK1—lung—esophageal cancer	0.000105	0.00174	CbGeAlD
Sunitinib—Hyperuricaemia—Methotrexate—esophageal cancer	0.000105	0.00193	CcSEcCtD
Sunitinib—FGR—digestive system—esophageal cancer	0.000105	0.00174	CbGeAlD
Sunitinib—RET—digestive system—esophageal cancer	0.000105	0.00174	CbGeAlD
Sunitinib—SNRK—lymph node—esophageal cancer	0.000104	0.00174	CbGeAlD
Sunitinib—OXSR1—lymph node—esophageal cancer	0.000104	0.00174	CbGeAlD
Sunitinib—INSR—lymph node—esophageal cancer	0.000104	0.00174	CbGeAlD
Sunitinib—STK38—lymph node—esophageal cancer	0.000103	0.00171	CbGeAlD
Sunitinib—RPS6KA2—lymph node—esophageal cancer	0.000103	0.00171	CbGeAlD
Sunitinib—BMP2K—lung—esophageal cancer	0.000103	0.00171	CbGeAlD
Sunitinib—CAMK2G—lung—esophageal cancer	0.000103	0.00171	CbGeAlD
Sunitinib—Renal failure acute—Capecitabine—esophageal cancer	0.000103	0.00189	CcSEcCtD
Sunitinib—KDR—epithelium—esophageal cancer	0.000102	0.0017	CbGeAlD
Sunitinib—YES1—trachea—esophageal cancer	0.000102	0.0017	CbGeAlD
Sunitinib—AURKC—lymph node—esophageal cancer	0.000102	0.0017	CbGeAlD
Sunitinib—LRRK2—lung—esophageal cancer	0.000102	0.00169	CbGeAlD
Sunitinib—PKN1—lymph node—esophageal cancer	0.000101	0.00168	CbGeAlD
Sunitinib—CSNK1G2—lymph node—esophageal cancer	0.000101	0.00168	CbGeAlD
Sunitinib—Hot flush—Capecitabine—esophageal cancer	0.000101	0.00187	CcSEcCtD
Sunitinib—TAOK3—trachea—esophageal cancer	0.000101	0.00168	CbGeAlD
Sunitinib—KDR—bronchus—esophageal cancer	0.000101	0.00168	CbGeAlD
Sunitinib—MAP2K5—bronchus—esophageal cancer	0.000101	0.00168	CbGeAlD
Sunitinib—PRKAA1—lung—esophageal cancer	0.0001	0.00167	CbGeAlD
Sunitinib—PDGFRA—trachea—esophageal cancer	0.0001	0.00167	CbGeAlD
Sunitinib—Menopausal symptoms—Capecitabine—esophageal cancer	0.0001	0.00185	CcSEcCtD
Sunitinib—PRPF4—lymph node—esophageal cancer	9.97e-05	0.00166	CbGeAlD
Sunitinib—Renal impairment—Capecitabine—esophageal cancer	9.94e-05	0.00184	CcSEcCtD
Sunitinib—FGFR2—digestive system—esophageal cancer	9.94e-05	0.00165	CbGeAlD
Sunitinib—PTK2B—lung—esophageal cancer	9.92e-05	0.00165	CbGeAlD
Sunitinib—Dermatitis bullous—Capecitabine—esophageal cancer	9.9e-05	0.00183	CcSEcCtD
Sunitinib—FLT4—lung—esophageal cancer	9.9e-05	0.00165	CbGeAlD
Sunitinib—JAK2—digestive system—esophageal cancer	9.89e-05	0.00164	CbGeAlD
Sunitinib—Respiratory failure—Methotrexate—esophageal cancer	9.88e-05	0.00183	CcSEcCtD
Sunitinib—Blood uric acid increased—Methotrexate—esophageal cancer	9.88e-05	0.00183	CcSEcCtD
Sunitinib—KDR—smooth muscle tissue—esophageal cancer	9.86e-05	0.00164	CbGeAlD
Sunitinib—CSF1R—bronchus—esophageal cancer	9.84e-05	0.00164	CbGeAlD
Sunitinib—PRPF4B—lymph node—esophageal cancer	9.83e-05	0.00163	CbGeAlD
Sunitinib—CSNK1E—lung—esophageal cancer	9.76e-05	0.00162	CbGeAlD
Sunitinib—FGFR1—lung—esophageal cancer	9.76e-05	0.00162	CbGeAlD
Sunitinib—Acute coronary syndrome—Cisplatin—esophageal cancer	9.75e-05	0.0018	CcSEcCtD
Sunitinib—FYN—digestive system—esophageal cancer	9.75e-05	0.00162	CbGeAlD
Sunitinib—Renal failure—Cisplatin—esophageal cancer	9.73e-05	0.0018	CcSEcCtD
Sunitinib—Pulmonary embolism—Methotrexate—esophageal cancer	9.71e-05	0.00179	CcSEcCtD
Sunitinib—Neuropathy peripheral—Cisplatin—esophageal cancer	9.7e-05	0.00179	CcSEcCtD
Sunitinib—STK39—lymph node—esophageal cancer	9.7e-05	0.00161	CbGeAlD
Sunitinib—Cardiac failure—Capecitabine—esophageal cancer	9.7e-05	0.00179	CcSEcCtD
Sunitinib—Cerebrovascular accident—Capecitabine—esophageal cancer	9.66e-05	0.00178	CcSEcCtD
Sunitinib—Stomatitis—Cisplatin—esophageal cancer	9.64e-05	0.00178	CcSEcCtD
Sunitinib—CSF1R—smooth muscle tissue—esophageal cancer	9.63e-05	0.0016	CbGeAlD
Sunitinib—IRAK4—lung—esophageal cancer	9.61e-05	0.0016	CbGeAlD
Sunitinib—CSNK2A1—lymph node—esophageal cancer	9.57e-05	0.00159	CbGeAlD
Sunitinib—Hyponatraemia—Capecitabine—esophageal cancer	9.5e-05	0.00176	CcSEcCtD
Sunitinib—Melaena—Methotrexate—esophageal cancer	9.48e-05	0.00175	CcSEcCtD
Sunitinib—Pain in extremity—Capecitabine—esophageal cancer	9.46e-05	0.00175	CcSEcCtD
Sunitinib—MYLK—lymph node—esophageal cancer	9.45e-05	0.00157	CbGeAlD
Sunitinib—ULK3—lung—esophageal cancer	9.4e-05	0.00156	CbGeAlD
Sunitinib—MAP2K2—lung—esophageal cancer	9.4e-05	0.00156	CbGeAlD
Sunitinib—Depressed level of consciousness—Methotrexate—esophageal cancer	9.37e-05	0.00173	CcSEcCtD
Sunitinib—Hepatobiliary disease—Cisplatin—esophageal cancer	9.36e-05	0.00173	CcSEcCtD
Sunitinib—MAP3K2—lung—esophageal cancer	9.33e-05	0.00155	CbGeAlD
Sunitinib—PLK4—lymph node—esophageal cancer	9.33e-05	0.00155	CbGeAlD
Sunitinib—STK4—lymph node—esophageal cancer	9.27e-05	0.00154	CbGeAlD
Sunitinib—Skin exfoliation—Methotrexate—esophageal cancer	9.27e-05	0.00171	CcSEcCtD
Sunitinib—MAP3K7—lung—esophageal cancer	9.24e-05	0.00154	CbGeAlD
Sunitinib—FLT1—digestive system—esophageal cancer	9.21e-05	0.00153	CbGeAlD
Sunitinib—TBK1—lung—esophageal cancer	9.14e-05	0.00152	CbGeAlD
Sunitinib—Face oedema—Capecitabine—esophageal cancer	9.14e-05	0.00169	CcSEcCtD
Sunitinib—PHKG2—lymph node—esophageal cancer	9.11e-05	0.00151	CbGeAlD
Sunitinib—TYK2—lung—esophageal cancer	9.08e-05	0.00151	CbGeAlD
Sunitinib—KIT—epithelium—esophageal cancer	9.07e-05	0.00151	CbGeAlD
Sunitinib—STK24—lymph node—esophageal cancer	9.06e-05	0.00151	CbGeAlD
Sunitinib—MAP2K5—trachea—esophageal cancer	9.05e-05	0.00151	CbGeAlD
Sunitinib—KDR—trachea—esophageal cancer	9.05e-05	0.00151	CbGeAlD
Sunitinib—Bradycardia—Cisplatin—esophageal cancer	9.04e-05	0.00167	CcSEcCtD
Sunitinib—IRAK1—lung—esophageal cancer	8.96e-05	0.00149	CbGeAlD
Sunitinib—DAPK2—lymph node—esophageal cancer	8.96e-05	0.00149	CbGeAlD
Sunitinib—KIT—bronchus—esophageal cancer	8.93e-05	0.00149	CbGeAlD
Sunitinib—Blood creatinine increased—Capecitabine—esophageal cancer	8.87e-05	0.00164	CcSEcCtD
Sunitinib—PDGFRB—epithelium—esophageal cancer	8.86e-05	0.00147	CbGeAlD
Sunitinib—CSF1R—trachea—esophageal cancer	8.83e-05	0.00147	CbGeAlD
Sunitinib—STK16—lymph node—esophageal cancer	8.81e-05	0.00146	CbGeAlD
Sunitinib—Dehydration—Capecitabine—esophageal cancer	8.8e-05	0.00163	CcSEcCtD
Sunitinib—YES1—digestive system—esophageal cancer	8.8e-05	0.00146	CbGeAlD
Sunitinib—RPS6KB1—lung—esophageal cancer	8.79e-05	0.00146	CbGeAlD
Sunitinib—Neoplasm—Methotrexate—esophageal cancer	8.77e-05	0.00162	CcSEcCtD
Sunitinib—Mouth ulceration—Methotrexate—esophageal cancer	8.77e-05	0.00162	CcSEcCtD
Sunitinib—Urinary tract disorder—Cisplatin—esophageal cancer	8.77e-05	0.00162	CcSEcCtD
Sunitinib—HIPK3—lymph node—esophageal cancer	8.76e-05	0.00146	CbGeAlD
Sunitinib—HIPK2—lymph node—esophageal cancer	8.76e-05	0.00146	CbGeAlD
Sunitinib—ALK—lymph node—esophageal cancer	8.76e-05	0.00146	CbGeAlD
Sunitinib—KIT—smooth muscle tissue—esophageal cancer	8.74e-05	0.00145	CbGeAlD
Sunitinib—Liver function test abnormal—Capecitabine—esophageal cancer	8.74e-05	0.00161	CcSEcCtD
Sunitinib—FGR—lung—esophageal cancer	8.74e-05	0.00145	CbGeAlD
Sunitinib—Connective tissue disorder—Cisplatin—esophageal cancer	8.73e-05	0.00161	CcSEcCtD
Sunitinib—PDGFRB—bronchus—esophageal cancer	8.73e-05	0.00145	CbGeAlD
Sunitinib—STK10—digestive system—esophageal cancer	8.72e-05	0.00145	CbGeAlD
Sunitinib—Urethral disorder—Cisplatin—esophageal cancer	8.71e-05	0.00161	CcSEcCtD
Sunitinib—AXL—lung—esophageal cancer	8.7e-05	0.00145	CbGeAlD
Sunitinib—TAOK3—digestive system—esophageal cancer	8.69e-05	0.00144	CbGeAlD
Sunitinib—Dry skin—Capecitabine—esophageal cancer	8.67e-05	0.0016	CcSEcCtD
Sunitinib—TNK1—lymph node—esophageal cancer	8.67e-05	0.00144	CbGeAlD
Sunitinib—RIOK2—lymph node—esophageal cancer	8.67e-05	0.00144	CbGeAlD
Sunitinib—Abdominal pain upper—Capecitabine—esophageal cancer	8.64e-05	0.0016	CcSEcCtD
Sunitinib—Pulmonary oedema—Methotrexate—esophageal cancer	8.64e-05	0.0016	CcSEcCtD
Sunitinib—PDGFRA—digestive system—esophageal cancer	8.63e-05	0.00144	CbGeAlD
Sunitinib—Hypokalaemia—Capecitabine—esophageal cancer	8.61e-05	0.00159	CcSEcCtD
Sunitinib—MAP4K1—lymph node—esophageal cancer	8.59e-05	0.00143	CbGeAlD
Sunitinib—PDGFRB—smooth muscle tissue—esophageal cancer	8.54e-05	0.00142	CbGeAlD
Sunitinib—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	8.52e-05	0.00157	CcSEcCtD
Sunitinib—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	8.52e-05	0.00157	CcSEcCtD
Sunitinib—Nasopharyngitis—Capecitabine—esophageal cancer	8.46e-05	0.00156	CcSEcCtD
Sunitinib—Sepsis—Methotrexate—esophageal cancer	8.42e-05	0.00156	CcSEcCtD
Sunitinib—DAPK3—lymph node—esophageal cancer	8.42e-05	0.0014	CbGeAlD
Sunitinib—SLK—lung—esophageal cancer	8.38e-05	0.00139	CbGeAlD
Sunitinib—Alanine aminotransferase increased—Capecitabine—esophageal cancer	8.35e-05	0.00154	CcSEcCtD
Sunitinib—Muscular weakness—Capecitabine—esophageal cancer	8.35e-05	0.00154	CcSEcCtD
Sunitinib—CLK2—lymph node—esophageal cancer	8.34e-05	0.00139	CbGeAlD
Sunitinib—MAP4K2—lymph node—esophageal cancer	8.3e-05	0.00138	CbGeAlD
Sunitinib—FGFR2—lung—esophageal cancer	8.3e-05	0.00138	CbGeAlD
Sunitinib—Eye disorder—Cisplatin—esophageal cancer	8.3e-05	0.00153	CcSEcCtD
Sunitinib—JAK2—lung—esophageal cancer	8.26e-05	0.00137	CbGeAlD
Sunitinib—Cardiac disorder—Cisplatin—esophageal cancer	8.24e-05	0.00152	CcSEcCtD
Sunitinib—Flushing—Cisplatin—esophageal cancer	8.24e-05	0.00152	CcSEcCtD
Sunitinib—Abdominal distension—Capecitabine—esophageal cancer	8.23e-05	0.00152	CcSEcCtD
Sunitinib—STK3—lymph node—esophageal cancer	8.19e-05	0.00136	CbGeAlD
Sunitinib—Dysphagia—Capecitabine—esophageal cancer	8.18e-05	0.00151	CcSEcCtD
Sunitinib—FYN—lung—esophageal cancer	8.14e-05	0.00135	CbGeAlD
Sunitinib—Immune system disorder—Cisplatin—esophageal cancer	8.02e-05	0.00148	CcSEcCtD
Sunitinib—KIT—trachea—esophageal cancer	8.02e-05	0.00133	CbGeAlD
Sunitinib—Mediastinal disorder—Cisplatin—esophageal cancer	8e-05	0.00148	CcSEcCtD
Sunitinib—MAP4K5—lung—esophageal cancer	7.96e-05	0.00132	CbGeAlD
Sunitinib—MAP3K3—lung—esophageal cancer	7.96e-05	0.00132	CbGeAlD
Sunitinib—Arrhythmia—Cisplatin—esophageal cancer	7.93e-05	0.00147	CcSEcCtD
Sunitinib—DYRK1A—lymph node—esophageal cancer	7.88e-05	0.00131	CbGeAlD
Sunitinib—Bronchitis—Capecitabine—esophageal cancer	7.87e-05	0.00145	CcSEcCtD
Sunitinib—Alopecia—Cisplatin—esophageal cancer	7.85e-05	0.00145	CcSEcCtD
Sunitinib—Abdominal discomfort—Capecitabine—esophageal cancer	7.84e-05	0.00145	CcSEcCtD
Sunitinib—Hepatic failure—Methotrexate—esophageal cancer	7.84e-05	0.00145	CcSEcCtD
Sunitinib—PDGFRB—trachea—esophageal cancer	7.83e-05	0.0013	CbGeAlD
Sunitinib—KDR—digestive system—esophageal cancer	7.79e-05	0.00129	CbGeAlD
Sunitinib—Pancytopenia—Capecitabine—esophageal cancer	7.77e-05	0.00143	CcSEcCtD
Sunitinib—Malnutrition—Cisplatin—esophageal cancer	7.73e-05	0.00143	CcSEcCtD
Sunitinib—Erythema—Cisplatin—esophageal cancer	7.73e-05	0.00143	CcSEcCtD
Sunitinib—MERTK—lymph node—esophageal cancer	7.7e-05	0.00128	CbGeAlD
Sunitinib—FLT1—lung—esophageal cancer	7.69e-05	0.00128	CbGeAlD
Sunitinib—Neutropenia—Capecitabine—esophageal cancer	7.65e-05	0.00141	CcSEcCtD
Sunitinib—Renal failure acute—Methotrexate—esophageal cancer	7.63e-05	0.00141	CcSEcCtD
Sunitinib—Flatulence—Cisplatin—esophageal cancer	7.62e-05	0.00141	CcSEcCtD
Sunitinib—EPHB6—lung—esophageal cancer	7.61e-05	0.00126	CbGeAlD
Sunitinib—Upper respiratory tract infection—Capecitabine—esophageal cancer	7.6e-05	0.0014	CcSEcCtD
Sunitinib—CSF1R—digestive system—esophageal cancer	7.6e-05	0.00126	CbGeAlD
Sunitinib—MAP4K4—lymph node—esophageal cancer	7.56e-05	0.00126	CbGeAlD
Sunitinib—NUAK2—lymph node—esophageal cancer	7.5e-05	0.00125	CbGeAlD
Sunitinib—FLT3—lymph node—esophageal cancer	7.45e-05	0.00124	CbGeAlD
Sunitinib—MAP3K12—lymph node—esophageal cancer	7.45e-05	0.00124	CbGeAlD
Sunitinib—Muscle spasms—Cisplatin—esophageal cancer	7.43e-05	0.00137	CcSEcCtD
Sunitinib—Weight decreased—Capecitabine—esophageal cancer	7.4e-05	0.00137	CcSEcCtD
Sunitinib—Hyperglycaemia—Capecitabine—esophageal cancer	7.38e-05	0.00136	CcSEcCtD
Sunitinib—YES1—lung—esophageal cancer	7.35e-05	0.00122	CbGeAlD
Sunitinib—RPS6KA3—lymph node—esophageal cancer	7.35e-05	0.00122	CbGeAlD
Sunitinib—Pneumonia—Capecitabine—esophageal cancer	7.34e-05	0.00136	CcSEcCtD
Sunitinib—MAP2K1—lymph node—esophageal cancer	7.3e-05	0.00121	CbGeAlD
Sunitinib—Infestation—Capecitabine—esophageal cancer	7.29e-05	0.00135	CcSEcCtD
Sunitinib—Infestation NOS—Capecitabine—esophageal cancer	7.29e-05	0.00135	CcSEcCtD
Sunitinib—STK10—lung—esophageal cancer	7.28e-05	0.00121	CbGeAlD
Sunitinib—Depression—Capecitabine—esophageal cancer	7.27e-05	0.00134	CcSEcCtD
Sunitinib—TAOK3—lung—esophageal cancer	7.26e-05	0.00121	CbGeAlD
Sunitinib—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	7.23e-05	0.00134	CcSEcCtD
Sunitinib—PDGFRA—lung—esophageal cancer	7.21e-05	0.0012	CbGeAlD
Sunitinib—CSNK1A1—lymph node—esophageal cancer	7.2e-05	0.0012	CbGeAlD
Sunitinib—Acute coronary syndrome—Capecitabine—esophageal cancer	7.19e-05	0.00133	CcSEcCtD
Sunitinib—Cerebrovascular accident—Methotrexate—esophageal cancer	7.19e-05	0.00133	CcSEcCtD
Sunitinib—Renal failure—Capecitabine—esophageal cancer	7.17e-05	0.00132	CcSEcCtD
Sunitinib—CLK1—lymph node—esophageal cancer	7.16e-05	0.00119	CbGeAlD
Sunitinib—Neuropathy peripheral—Capecitabine—esophageal cancer	7.15e-05	0.00132	CcSEcCtD
Sunitinib—Anaemia—Cisplatin—esophageal cancer	7.15e-05	0.00132	CcSEcCtD
Sunitinib—Stomatitis—Capecitabine—esophageal cancer	7.11e-05	0.00131	CcSEcCtD
Sunitinib—Urinary tract infection—Capecitabine—esophageal cancer	7.09e-05	0.00131	CcSEcCtD
Sunitinib—BMP2K—lymph node—esophageal cancer	7.03e-05	0.00117	CbGeAlD
Sunitinib—CAMK2G—lymph node—esophageal cancer	7.03e-05	0.00117	CbGeAlD
Sunitinib—LRRK2—lymph node—esophageal cancer	6.96e-05	0.00116	CbGeAlD
Sunitinib—ABCC4—bronchus—esophageal cancer	6.95e-05	0.00116	CbGeAlD
Sunitinib—Leukopenia—Cisplatin—esophageal cancer	6.92e-05	0.00128	CcSEcCtD
Sunitinib—KIT—digestive system—esophageal cancer	6.9e-05	0.00115	CbGeAlD
Sunitinib—Hepatobiliary disease—Capecitabine—esophageal cancer	6.9e-05	0.00127	CcSEcCtD
Sunitinib—Epistaxis—Capecitabine—esophageal cancer	6.88e-05	0.00127	CcSEcCtD
Sunitinib—PRKAA1—lymph node—esophageal cancer	6.86e-05	0.00114	CbGeAlD
Sunitinib—PTK2B—lymph node—esophageal cancer	6.79e-05	0.00113	CbGeAlD
Sunitinib—FLT4—lymph node—esophageal cancer	6.77e-05	0.00113	CbGeAlD
Sunitinib—PDGFRB—digestive system—esophageal cancer	6.74e-05	0.00112	CbGeAlD
Sunitinib—Convulsion—Cisplatin—esophageal cancer	6.7e-05	0.00124	CcSEcCtD
Sunitinib—CSNK1E—lymph node—esophageal cancer	6.68e-05	0.00111	CbGeAlD
Sunitinib—FGFR1—lymph node—esophageal cancer	6.68e-05	0.00111	CbGeAlD
Sunitinib—Bradycardia—Capecitabine—esophageal cancer	6.66e-05	0.00123	CcSEcCtD
Sunitinib—Myalgia—Cisplatin—esophageal cancer	6.58e-05	0.00122	CcSEcCtD
Sunitinib—Haemoglobin—Capecitabine—esophageal cancer	6.58e-05	0.00122	CcSEcCtD
Sunitinib—IRAK4—lymph node—esophageal cancer	6.57e-05	0.00109	CbGeAlD
Sunitinib—Hepatitis—Capecitabine—esophageal cancer	6.55e-05	0.00121	CcSEcCtD
Sunitinib—Haemorrhage—Capecitabine—esophageal cancer	6.55e-05	0.00121	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	6.54e-05	0.00121	CcSEcCtD
Sunitinib—Hypoaesthesia—Capecitabine—esophageal cancer	6.51e-05	0.0012	CcSEcCtD
Sunitinib—Liver function test abnormal—Methotrexate—esophageal cancer	6.5e-05	0.0012	CcSEcCtD
Sunitinib—KDR—lung—esophageal cancer	6.5e-05	0.00108	CbGeAlD
Sunitinib—MAP2K5—lung—esophageal cancer	6.5e-05	0.00108	CbGeAlD
Sunitinib—Urinary tract disorder—Capecitabine—esophageal cancer	6.47e-05	0.00119	CcSEcCtD
Sunitinib—Oedema peripheral—Capecitabine—esophageal cancer	6.45e-05	0.00119	CcSEcCtD
Sunitinib—Connective tissue disorder—Capecitabine—esophageal cancer	6.43e-05	0.00119	CcSEcCtD
Sunitinib—MAP2K2—lymph node—esophageal cancer	6.43e-05	0.00107	CbGeAlD
Sunitinib—ULK3—lymph node—esophageal cancer	6.43e-05	0.00107	CbGeAlD
Sunitinib—Urethral disorder—Capecitabine—esophageal cancer	6.42e-05	0.00119	CcSEcCtD
Sunitinib—MAP3K2—lymph node—esophageal cancer	6.38e-05	0.00106	CbGeAlD
Sunitinib—CSF1R—lung—esophageal cancer	6.35e-05	0.00106	CbGeAlD
Sunitinib—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	6.34e-05	0.00117	CcSEcCtD
Sunitinib—MAP3K7—lymph node—esophageal cancer	6.32e-05	0.00105	CbGeAlD
Sunitinib—Oedema—Cisplatin—esophageal cancer	6.31e-05	0.00117	CcSEcCtD
Sunitinib—Infection—Cisplatin—esophageal cancer	6.27e-05	0.00116	CcSEcCtD
Sunitinib—TBK1—lymph node—esophageal cancer	6.25e-05	0.00104	CbGeAlD
Sunitinib—TYK2—lymph node—esophageal cancer	6.21e-05	0.00103	CbGeAlD
Sunitinib—Erythema multiforme—Capecitabine—esophageal cancer	6.19e-05	0.00114	CcSEcCtD
Sunitinib—Nervous system disorder—Cisplatin—esophageal cancer	6.19e-05	0.00114	CcSEcCtD
Sunitinib—Thrombocytopenia—Cisplatin—esophageal cancer	6.18e-05	0.00114	CcSEcCtD
Sunitinib—Skin disorder—Cisplatin—esophageal cancer	6.13e-05	0.00113	CcSEcCtD
Sunitinib—IRAK1—lymph node—esophageal cancer	6.13e-05	0.00102	CbGeAlD
Sunitinib—Eye disorder—Capecitabine—esophageal cancer	6.12e-05	0.00113	CcSEcCtD
Sunitinib—Flushing—Capecitabine—esophageal cancer	6.08e-05	0.00112	CcSEcCtD
Sunitinib—Cardiac disorder—Capecitabine—esophageal cancer	6.08e-05	0.00112	CcSEcCtD
Sunitinib—Anorexia—Cisplatin—esophageal cancer	6.01e-05	0.00111	CcSEcCtD
Sunitinib—RPS6KB1—lymph node—esophageal cancer	6.01e-05	0.001	CbGeAlD
Sunitinib—FGR—lymph node—esophageal cancer	5.97e-05	0.000993	CbGeAlD
Sunitinib—RET—lymph node—esophageal cancer	5.97e-05	0.000993	CbGeAlD
Sunitinib—Pancreatitis—Methotrexate—esophageal cancer	5.97e-05	0.0011	CcSEcCtD
Sunitinib—AXL—lymph node—esophageal cancer	5.95e-05	0.00099	CbGeAlD
Sunitinib—Angiopathy—Capecitabine—esophageal cancer	5.94e-05	0.0011	CcSEcCtD
Sunitinib—Immune system disorder—Capecitabine—esophageal cancer	5.91e-05	0.00109	CcSEcCtD
Sunitinib—Mediastinal disorder—Capecitabine—esophageal cancer	5.9e-05	0.00109	CcSEcCtD
Sunitinib—Chills—Capecitabine—esophageal cancer	5.87e-05	0.00109	CcSEcCtD
Sunitinib—Arrhythmia—Capecitabine—esophageal cancer	5.85e-05	0.00108	CcSEcCtD
Sunitinib—Abdominal discomfort—Methotrexate—esophageal cancer	5.84e-05	0.00108	CcSEcCtD
Sunitinib—Alopecia—Capecitabine—esophageal cancer	5.79e-05	0.00107	CcSEcCtD
Sunitinib—Pancytopenia—Methotrexate—esophageal cancer	5.78e-05	0.00107	CcSEcCtD
Sunitinib—KIT—lung—esophageal cancer	5.76e-05	0.000958	CbGeAlD
Sunitinib—Musculoskeletal discomfort—Cisplatin—esophageal cancer	5.75e-05	0.00106	CcSEcCtD
Sunitinib—Mental disorder—Capecitabine—esophageal cancer	5.74e-05	0.00106	CcSEcCtD
Sunitinib—SLK—lymph node—esophageal cancer	5.73e-05	0.000952	CbGeAlD
Sunitinib—Erythema—Capecitabine—esophageal cancer	5.7e-05	0.00105	CcSEcCtD
Sunitinib—Malnutrition—Capecitabine—esophageal cancer	5.7e-05	0.00105	CcSEcCtD
Sunitinib—Neutropenia—Methotrexate—esophageal cancer	5.69e-05	0.00105	CcSEcCtD
Sunitinib—Paraesthesia—Cisplatin—esophageal cancer	5.67e-05	0.00105	CcSEcCtD
Sunitinib—Upper respiratory tract infection—Methotrexate—esophageal cancer	5.66e-05	0.00105	CcSEcCtD
Sunitinib—JAK2—lymph node—esophageal cancer	5.65e-05	0.000939	CbGeAlD
Sunitinib—PDGFRB—lung—esophageal cancer	5.63e-05	0.000936	CbGeAlD
Sunitinib—Dyspnoea—Cisplatin—esophageal cancer	5.63e-05	0.00104	CcSEcCtD
Sunitinib—Flatulence—Capecitabine—esophageal cancer	5.62e-05	0.00104	CcSEcCtD
Sunitinib—Dysgeusia—Capecitabine—esophageal cancer	5.58e-05	0.00103	CcSEcCtD
Sunitinib—FYN—lymph node—esophageal cancer	5.57e-05	0.000926	CbGeAlD
Sunitinib—Back pain—Capecitabine—esophageal cancer	5.51e-05	0.00102	CcSEcCtD
Sunitinib—Decreased appetite—Cisplatin—esophageal cancer	5.49e-05	0.00101	CcSEcCtD
Sunitinib—Muscle spasms—Capecitabine—esophageal cancer	5.48e-05	0.00101	CcSEcCtD
Sunitinib—Pneumonia—Methotrexate—esophageal cancer	5.46e-05	0.00101	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Cisplatin—esophageal cancer	5.45e-05	0.00101	CcSEcCtD
Sunitinib—MAP4K5—lymph node—esophageal cancer	5.44e-05	0.000905	CbGeAlD
Sunitinib—MAP3K3—lymph node—esophageal cancer	5.44e-05	0.000905	CbGeAlD
Sunitinib—Infestation NOS—Methotrexate—esophageal cancer	5.43e-05	0.001	CcSEcCtD
Sunitinib—Infestation—Methotrexate—esophageal cancer	5.43e-05	0.001	CcSEcCtD
Sunitinib—Depression—Methotrexate—esophageal cancer	5.41e-05	0.001	CcSEcCtD
Sunitinib—Pain—Cisplatin—esophageal cancer	5.4e-05	0.000997	CcSEcCtD
Sunitinib—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	5.38e-05	0.000994	CcSEcCtD
Sunitinib—ABCC4—digestive system—esophageal cancer	5.37e-05	0.000892	CbGeAlD
Sunitinib—Renal failure—Methotrexate—esophageal cancer	5.34e-05	0.000986	CcSEcCtD
Sunitinib—Stomatitis—Methotrexate—esophageal cancer	5.29e-05	0.000978	CcSEcCtD
Sunitinib—Anaemia—Capecitabine—esophageal cancer	5.27e-05	0.000973	CcSEcCtD
Sunitinib—FLT1—lymph node—esophageal cancer	5.26e-05	0.000875	CbGeAlD
Sunitinib—EPHB6—lymph node—esophageal cancer	5.2e-05	0.000865	CbGeAlD
Sunitinib—ABCC2—digestive system—esophageal cancer	5.2e-05	0.000864	CbGeAlD
Sunitinib—Hepatobiliary disease—Methotrexate—esophageal cancer	5.13e-05	0.000948	CcSEcCtD
Sunitinib—Epistaxis—Methotrexate—esophageal cancer	5.12e-05	0.000946	CcSEcCtD
Sunitinib—Leukopenia—Capecitabine—esophageal cancer	5.1e-05	0.000942	CcSEcCtD
Sunitinib—YES1—lymph node—esophageal cancer	5.03e-05	0.000836	CbGeAlD
Sunitinib—Body temperature increased—Cisplatin—esophageal cancer	4.99e-05	0.000921	CcSEcCtD
Sunitinib—STK10—lymph node—esophageal cancer	4.98e-05	0.000828	CbGeAlD
Sunitinib—Cough—Capecitabine—esophageal cancer	4.97e-05	0.000919	CcSEcCtD
Sunitinib—TAOK3—lymph node—esophageal cancer	4.96e-05	0.000825	CbGeAlD
Sunitinib—PDGFRA—lymph node—esophageal cancer	4.93e-05	0.00082	CbGeAlD
Sunitinib—Hypertension—Capecitabine—esophageal cancer	4.92e-05	0.000909	CcSEcCtD
Sunitinib—Haemoglobin—Methotrexate—esophageal cancer	4.9e-05	0.000905	CcSEcCtD
Sunitinib—Hepatitis—Methotrexate—esophageal cancer	4.87e-05	0.0009	CcSEcCtD
Sunitinib—Haemorrhage—Methotrexate—esophageal cancer	4.87e-05	0.0009	CcSEcCtD
Sunitinib—Arthralgia—Capecitabine—esophageal cancer	4.85e-05	0.000896	CcSEcCtD
Sunitinib—Chest pain—Capecitabine—esophageal cancer	4.85e-05	0.000896	CcSEcCtD
Sunitinib—Myalgia—Capecitabine—esophageal cancer	4.85e-05	0.000896	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	4.82e-05	0.00089	CcSEcCtD
Sunitinib—Urinary tract disorder—Methotrexate—esophageal cancer	4.81e-05	0.000889	CcSEcCtD
Sunitinib—Urethral disorder—Methotrexate—esophageal cancer	4.78e-05	0.000883	CcSEcCtD
Sunitinib—Dry mouth—Capecitabine—esophageal cancer	4.75e-05	0.000877	CcSEcCtD
Sunitinib—Oedema—Capecitabine—esophageal cancer	4.65e-05	0.000859	CcSEcCtD
Sunitinib—Hypersensitivity—Cisplatin—esophageal cancer	4.65e-05	0.000859	CcSEcCtD
Sunitinib—Infection—Capecitabine—esophageal cancer	4.62e-05	0.000854	CcSEcCtD
Sunitinib—Erythema multiforme—Methotrexate—esophageal cancer	4.61e-05	0.000851	CcSEcCtD
Sunitinib—Shock—Capecitabine—esophageal cancer	4.58e-05	0.000845	CcSEcCtD
Sunitinib—Nervous system disorder—Capecitabine—esophageal cancer	4.56e-05	0.000843	CcSEcCtD
Sunitinib—Eye disorder—Methotrexate—esophageal cancer	4.55e-05	0.000841	CcSEcCtD
Sunitinib—Thrombocytopenia—Capecitabine—esophageal cancer	4.55e-05	0.000841	CcSEcCtD
Sunitinib—Asthenia—Cisplatin—esophageal cancer	4.53e-05	0.000836	CcSEcCtD
Sunitinib—Cardiac disorder—Methotrexate—esophageal cancer	4.52e-05	0.000836	CcSEcCtD
Sunitinib—Skin disorder—Capecitabine—esophageal cancer	4.52e-05	0.000835	CcSEcCtD
Sunitinib—ABCC4—lung—esophageal cancer	4.48e-05	0.000745	CbGeAlD
Sunitinib—KDR—lymph node—esophageal cancer	4.45e-05	0.00074	CbGeAlD
Sunitinib—MAP2K5—lymph node—esophageal cancer	4.45e-05	0.00074	CbGeAlD
Sunitinib—Anorexia—Capecitabine—esophageal cancer	4.43e-05	0.000819	CcSEcCtD
Sunitinib—Angiopathy—Methotrexate—esophageal cancer	4.42e-05	0.000817	CcSEcCtD
Sunitinib—Immune system disorder—Methotrexate—esophageal cancer	4.4e-05	0.000813	CcSEcCtD
Sunitinib—Mediastinal disorder—Methotrexate—esophageal cancer	4.39e-05	0.000811	CcSEcCtD
Sunitinib—Chills—Methotrexate—esophageal cancer	4.37e-05	0.000808	CcSEcCtD
Sunitinib—CSF1R—lymph node—esophageal cancer	4.34e-05	0.000722	CbGeAlD
Sunitinib—Diarrhoea—Cisplatin—esophageal cancer	4.32e-05	0.000798	CcSEcCtD
Sunitinib—Alopecia—Methotrexate—esophageal cancer	4.31e-05	0.000796	CcSEcCtD
Sunitinib—Mental disorder—Methotrexate—esophageal cancer	4.27e-05	0.000789	CcSEcCtD
Sunitinib—Malnutrition—Methotrexate—esophageal cancer	4.24e-05	0.000784	CcSEcCtD
Sunitinib—Erythema—Methotrexate—esophageal cancer	4.24e-05	0.000784	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Capecitabine—esophageal cancer	4.24e-05	0.000783	CcSEcCtD
Sunitinib—Insomnia—Capecitabine—esophageal cancer	4.21e-05	0.000777	CcSEcCtD
Sunitinib—Paraesthesia—Capecitabine—esophageal cancer	4.18e-05	0.000772	CcSEcCtD
Sunitinib—Dysgeusia—Methotrexate—esophageal cancer	4.15e-05	0.000767	CcSEcCtD
Sunitinib—Dyspnoea—Capecitabine—esophageal cancer	4.15e-05	0.000766	CcSEcCtD
Sunitinib—Back pain—Methotrexate—esophageal cancer	4.1e-05	0.000758	CcSEcCtD
Sunitinib—Dyspepsia—Capecitabine—esophageal cancer	4.09e-05	0.000756	CcSEcCtD
Sunitinib—Decreased appetite—Capecitabine—esophageal cancer	4.04e-05	0.000747	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Capecitabine—esophageal cancer	4.02e-05	0.000742	CcSEcCtD
Sunitinib—Vomiting—Cisplatin—esophageal cancer	4.01e-05	0.000741	CcSEcCtD
Sunitinib—Fatigue—Capecitabine—esophageal cancer	4.01e-05	0.000741	CcSEcCtD
Sunitinib—Rash—Cisplatin—esophageal cancer	3.98e-05	0.000735	CcSEcCtD
Sunitinib—Constipation—Capecitabine—esophageal cancer	3.98e-05	0.000735	CcSEcCtD
Sunitinib—Pain—Capecitabine—esophageal cancer	3.98e-05	0.000735	CcSEcCtD
Sunitinib—Dermatitis—Cisplatin—esophageal cancer	3.97e-05	0.000734	CcSEcCtD
Sunitinib—KIT—lymph node—esophageal cancer	3.94e-05	0.000655	CbGeAlD
Sunitinib—Anaemia—Methotrexate—esophageal cancer	3.92e-05	0.000724	CcSEcCtD
Sunitinib—PDGFRB—lymph node—esophageal cancer	3.85e-05	0.00064	CbGeAlD
Sunitinib—Gastrointestinal pain—Capecitabine—esophageal cancer	3.8e-05	0.000703	CcSEcCtD
Sunitinib—Leukopenia—Methotrexate—esophageal cancer	3.8e-05	0.000702	CcSEcCtD
Sunitinib—Nausea—Cisplatin—esophageal cancer	3.75e-05	0.000692	CcSEcCtD
Sunitinib—Cough—Methotrexate—esophageal cancer	3.7e-05	0.000684	CcSEcCtD
Sunitinib—Body temperature increased—Capecitabine—esophageal cancer	3.68e-05	0.000679	CcSEcCtD
Sunitinib—Abdominal pain—Capecitabine—esophageal cancer	3.68e-05	0.000679	CcSEcCtD
Sunitinib—Convulsion—Methotrexate—esophageal cancer	3.68e-05	0.000679	CcSEcCtD
Sunitinib—Myalgia—Methotrexate—esophageal cancer	3.61e-05	0.000667	CcSEcCtD
Sunitinib—Arthralgia—Methotrexate—esophageal cancer	3.61e-05	0.000667	CcSEcCtD
Sunitinib—Chest pain—Methotrexate—esophageal cancer	3.61e-05	0.000667	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	3.59e-05	0.000663	CcSEcCtD
Sunitinib—CYP3A5—digestive system—esophageal cancer	3.52e-05	0.000585	CbGeAlD
Sunitinib—Infection—Methotrexate—esophageal cancer	3.44e-05	0.000635	CcSEcCtD
Sunitinib—Hypersensitivity—Capecitabine—esophageal cancer	3.43e-05	0.000633	CcSEcCtD
Sunitinib—Nervous system disorder—Methotrexate—esophageal cancer	3.4e-05	0.000627	CcSEcCtD
Sunitinib—Thrombocytopenia—Methotrexate—esophageal cancer	3.39e-05	0.000626	CcSEcCtD
Sunitinib—Skin disorder—Methotrexate—esophageal cancer	3.36e-05	0.000621	CcSEcCtD
Sunitinib—Asthenia—Capecitabine—esophageal cancer	3.34e-05	0.000616	CcSEcCtD
Sunitinib—Anorexia—Methotrexate—esophageal cancer	3.3e-05	0.00061	CcSEcCtD
Sunitinib—Pruritus—Capecitabine—esophageal cancer	3.29e-05	0.000608	CcSEcCtD
Sunitinib—Diarrhoea—Capecitabine—esophageal cancer	3.18e-05	0.000588	CcSEcCtD
Sunitinib—ABCG2—lung—esophageal cancer	3.16e-05	0.000526	CbGeAlD
Sunitinib—Musculoskeletal discomfort—Methotrexate—esophageal cancer	3.15e-05	0.000583	CcSEcCtD
Sunitinib—Insomnia—Methotrexate—esophageal cancer	3.13e-05	0.000579	CcSEcCtD
Sunitinib—Paraesthesia—Methotrexate—esophageal cancer	3.11e-05	0.000574	CcSEcCtD
Sunitinib—Dyspnoea—Methotrexate—esophageal cancer	3.09e-05	0.00057	CcSEcCtD
Sunitinib—Dizziness—Capecitabine—esophageal cancer	3.08e-05	0.000568	CcSEcCtD
Sunitinib—ABCC4—lymph node—esophageal cancer	3.07e-05	0.00051	CbGeAlD
Sunitinib—Dyspepsia—Methotrexate—esophageal cancer	3.05e-05	0.000563	CcSEcCtD
Sunitinib—Decreased appetite—Methotrexate—esophageal cancer	3.01e-05	0.000556	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Methotrexate—esophageal cancer	2.99e-05	0.000552	CcSEcCtD
Sunitinib—Fatigue—Methotrexate—esophageal cancer	2.99e-05	0.000551	CcSEcCtD
Sunitinib—ABCC2—lymph node—esophageal cancer	2.97e-05	0.000493	CbGeAlD
Sunitinib—Pain—Methotrexate—esophageal cancer	2.96e-05	0.000547	CcSEcCtD
Sunitinib—Vomiting—Capecitabine—esophageal cancer	2.96e-05	0.000546	CcSEcCtD
Sunitinib—CYP3A5—lung—esophageal cancer	2.94e-05	0.000488	CbGeAlD
Sunitinib—Rash—Capecitabine—esophageal cancer	2.93e-05	0.000542	CcSEcCtD
Sunitinib—Dermatitis—Capecitabine—esophageal cancer	2.93e-05	0.000541	CcSEcCtD
Sunitinib—Headache—Capecitabine—esophageal cancer	2.91e-05	0.000538	CcSEcCtD
Sunitinib—Gastrointestinal pain—Methotrexate—esophageal cancer	2.83e-05	0.000523	CcSEcCtD
Sunitinib—Nausea—Capecitabine—esophageal cancer	2.76e-05	0.00051	CcSEcCtD
Sunitinib—Body temperature increased—Methotrexate—esophageal cancer	2.74e-05	0.000506	CcSEcCtD
Sunitinib—Abdominal pain—Methotrexate—esophageal cancer	2.74e-05	0.000506	CcSEcCtD
Sunitinib—CYP3A4—digestive system—esophageal cancer	2.64e-05	0.000439	CbGeAlD
Sunitinib—Hypersensitivity—Methotrexate—esophageal cancer	2.55e-05	0.000471	CcSEcCtD
Sunitinib—Asthenia—Methotrexate—esophageal cancer	2.48e-05	0.000459	CcSEcCtD
Sunitinib—ABCB1—epithelium—esophageal cancer	2.46e-05	0.000408	CbGeAlD
Sunitinib—Pruritus—Methotrexate—esophageal cancer	2.45e-05	0.000453	CcSEcCtD
Sunitinib—KCNH2—lymph node—esophageal cancer	2.43e-05	0.000404	CbGeAlD
Sunitinib—Diarrhoea—Methotrexate—esophageal cancer	2.37e-05	0.000438	CcSEcCtD
Sunitinib—Dizziness—Methotrexate—esophageal cancer	2.29e-05	0.000423	CcSEcCtD
Sunitinib—Vomiting—Methotrexate—esophageal cancer	2.2e-05	0.000407	CcSEcCtD
Sunitinib—Rash—Methotrexate—esophageal cancer	2.18e-05	0.000403	CcSEcCtD
Sunitinib—Dermatitis—Methotrexate—esophageal cancer	2.18e-05	0.000403	CcSEcCtD
Sunitinib—ABCB1—trachea—esophageal cancer	2.17e-05	0.000361	CbGeAlD
Sunitinib—Headache—Methotrexate—esophageal cancer	2.17e-05	0.000401	CcSEcCtD
Sunitinib—ABCG2—lymph node—esophageal cancer	2.16e-05	0.00036	CbGeAlD
Sunitinib—Nausea—Methotrexate—esophageal cancer	2.06e-05	0.00038	CcSEcCtD
Sunitinib—ABCB1—digestive system—esophageal cancer	1.87e-05	0.000311	CbGeAlD
Sunitinib—ABCB1—lung—esophageal cancer	1.56e-05	0.000259	CbGeAlD
Sunitinib—ABCB1—lymph node—esophageal cancer	1.07e-05	0.000177	CbGeAlD
Sunitinib—FGFR2—Signaling Pathways—ERBB2—esophageal cancer	4.54e-07	4.76e-06	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—EGFR—esophageal cancer	4.54e-07	4.75e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—ABCB1—esophageal cancer	4.53e-07	4.74e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—EP300—esophageal cancer	4.53e-07	4.74e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—EGFR—esophageal cancer	4.53e-07	4.74e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—NOS3—esophageal cancer	4.53e-07	4.74e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—NOS3—esophageal cancer	4.51e-07	4.73e-06	CbGpPWpGaD
Sunitinib—KIT—Disease—MYC—esophageal cancer	4.51e-07	4.73e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—MYC—esophageal cancer	4.51e-07	4.72e-06	CbGpPWpGaD
Sunitinib—FGFR2—Disease—EGFR—esophageal cancer	4.5e-07	4.71e-06	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—PIK3CA—esophageal cancer	4.49e-07	4.7e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—CDKN1A—esophageal cancer	4.48e-07	4.69e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—ERBB2—esophageal cancer	4.46e-07	4.67e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—ERBB2—esophageal cancer	4.46e-07	4.67e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—CDKN1A—esophageal cancer	4.45e-07	4.66e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CYP26A1—esophageal cancer	4.45e-07	4.66e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—EP300—esophageal cancer	4.42e-07	4.63e-06	CbGpPWpGaD
Sunitinib—KIT—Disease—EGFR—esophageal cancer	4.42e-07	4.62e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—CCND1—esophageal cancer	4.41e-07	4.62e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—EGFR—esophageal cancer	4.41e-07	4.62e-06	CbGpPWpGaD
Sunitinib—IRAK1—Immune System—PIK3CA—esophageal cancer	4.41e-07	4.62e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—EP300—esophageal cancer	4.38e-07	4.59e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CREBBP—esophageal cancer	4.38e-07	4.59e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CREBBP—esophageal cancer	4.36e-07	4.56e-06	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—TP53—esophageal cancer	4.35e-07	4.55e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—MYC—esophageal cancer	4.34e-07	4.55e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ALOX15—esophageal cancer	4.34e-07	4.54e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—MYC—esophageal cancer	4.31e-07	4.52e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—MYC—esophageal cancer	4.28e-07	4.49e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—EGFR—esophageal cancer	4.28e-07	4.48e-06	CbGpPWpGaD
Sunitinib—TYK2—Immune System—PIK3CA—esophageal cancer	4.28e-07	4.48e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—MYC—esophageal cancer	4.27e-07	4.47e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—CDKN1A—esophageal cancer	4.27e-07	4.47e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—EP300—esophageal cancer	4.26e-07	4.46e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—CDKN1A—esophageal cancer	4.25e-07	4.45e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—EGFR—esophageal cancer	4.25e-07	4.45e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—EP300—esophageal cancer	4.24e-07	4.44e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—ERBB2—esophageal cancer	4.23e-07	4.43e-06	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—PIK3CA—esophageal cancer	4.23e-07	4.43e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—CREBBP—esophageal cancer	4.22e-07	4.42e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—ERBB2—esophageal cancer	4.22e-07	4.42e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—EGFR—esophageal cancer	4.22e-07	4.42e-06	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—PIK3CA—esophageal cancer	4.21e-07	4.41e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—EGFR—esophageal cancer	4.19e-07	4.39e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—CREBBP—esophageal cancer	4.19e-07	4.38e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—CCND1—esophageal cancer	4.19e-07	4.38e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—MYC—esophageal cancer	4.18e-07	4.38e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—MYC—esophageal cancer	4.18e-07	4.38e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—EGFR—esophageal cancer	4.18e-07	4.38e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—EGFR—esophageal cancer	4.18e-07	4.38e-06	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—PIK3CA—esophageal cancer	4.18e-07	4.37e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—NOS3—esophageal cancer	4.17e-07	4.36e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CREBBP—esophageal cancer	4.16e-07	4.36e-06	CbGpPWpGaD
Sunitinib—KIT—Immune System—PIK3CA—esophageal cancer	4.15e-07	4.35e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—PIK3CA—esophageal cancer	4.15e-07	4.35e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—CYP1B1—esophageal cancer	4.15e-07	4.34e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—GSTO1—esophageal cancer	4.14e-07	4.33e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—TPI1—esophageal cancer	4.14e-07	4.33e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—EGFR—esophageal cancer	4.09e-07	4.29e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—EGFR—esophageal cancer	4.09e-07	4.29e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—EGFR—esophageal cancer	4.09e-07	4.28e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—EGFR—esophageal cancer	4.08e-07	4.27e-06	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—TP53—esophageal cancer	4.08e-07	4.27e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—MYC—esophageal cancer	4.08e-07	4.27e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—NOS3—esophageal cancer	4.07e-07	4.26e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—CCND1—esophageal cancer	4.06e-07	4.26e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—EP300—esophageal cancer	4.06e-07	4.25e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—CDKN1A—esophageal cancer	4.05e-07	4.24e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—EP300—esophageal cancer	4.05e-07	4.24e-06	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—TP53—esophageal cancer	4.04e-07	4.23e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—CCND1—esophageal cancer	4.01e-07	4.2e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—EGFR—esophageal cancer	3.99e-07	4.18e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by GPCR—PIK3CA—esophageal cancer	3.97e-07	4.16e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ALDOB—esophageal cancer	3.97e-07	4.15e-06	CbGpPWpGaD
Sunitinib—TYK2—Disease—PIK3CA—esophageal cancer	3.95e-07	4.14e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—MYC—esophageal cancer	3.95e-07	4.13e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—CCND1—esophageal cancer	3.94e-07	4.13e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—CCND1—esophageal cancer	3.94e-07	4.13e-06	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—PIK3CA—esophageal cancer	3.94e-07	4.13e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—EGFR—esophageal cancer	3.93e-07	4.12e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—CDKN1A—esophageal cancer	3.93e-07	4.12e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—PIK3CA—esophageal cancer	3.93e-07	4.11e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—NOS3—esophageal cancer	3.92e-07	4.11e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—EGFR—esophageal cancer	3.91e-07	4.09e-06	CbGpPWpGaD
Sunitinib—JAK2—GPCR downstream signaling—PIK3CA—esophageal cancer	3.91e-07	4.09e-06	CbGpPWpGaD
Sunitinib—FGFR2—Disease—PIK3CA—esophageal cancer	3.9e-07	4.09e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—CYP19A1—esophageal cancer	3.9e-07	4.08e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—NOS3—esophageal cancer	3.9e-07	4.08e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—ERBB2—esophageal cancer	3.9e-07	4.08e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—CDKN1A—esophageal cancer	3.88e-07	4.07e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—EGFR—esophageal cancer	3.86e-07	4.04e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—EP300—esophageal cancer	3.85e-07	4.03e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—MYC—esophageal cancer	3.85e-07	4.03e-06	CbGpPWpGaD
Sunitinib—KIT—Disease—PIK3CA—esophageal cancer	3.83e-07	4.01e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—PIK3CA—esophageal cancer	3.83e-07	4.01e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—GAPDH—esophageal cancer	3.82e-07	4e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—CDKN1A—esophageal cancer	3.81e-07	3.99e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—CDKN1A—esophageal cancer	3.81e-07	3.99e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—ERBB2—esophageal cancer	3.8e-07	3.98e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CRABP1—esophageal cancer	3.78e-07	3.96e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—NOS3—esophageal cancer	3.78e-07	3.96e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—EGFR—esophageal cancer	3.77e-07	3.94e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—NOS3—esophageal cancer	3.75e-07	3.92e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—EP300—esophageal cancer	3.74e-07	3.92e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—CCND1—esophageal cancer	3.74e-07	3.92e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—EGFR—esophageal cancer	3.74e-07	3.91e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—CCND1—esophageal cancer	3.73e-07	3.91e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—NOS3—esophageal cancer	3.73e-07	3.9e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—PIK3CA—esophageal cancer	3.71e-07	3.89e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—MYC—esophageal cancer	3.71e-07	3.89e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—TP53—esophageal cancer	3.7e-07	3.88e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—EP300—esophageal cancer	3.69e-07	3.87e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—MYC—esophageal cancer	3.69e-07	3.87e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—PIK3CA—esophageal cancer	3.69e-07	3.86e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—ERBB2—esophageal cancer	3.67e-07	3.84e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—PIK3CA—esophageal cancer	3.66e-07	3.84e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—ERBB2—esophageal cancer	3.65e-07	3.82e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—PIK3CA—esophageal cancer	3.64e-07	3.81e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—EGFR—esophageal cancer	3.63e-07	3.8e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—EP300—esophageal cancer	3.63e-07	3.8e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—EP300—esophageal cancer	3.63e-07	3.8e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—PIK3CA—esophageal cancer	3.63e-07	3.8e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—PIK3CA—esophageal cancer	3.63e-07	3.8e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—CDKN1A—esophageal cancer	3.62e-07	3.79e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—EGFR—esophageal cancer	3.61e-07	3.78e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—CDKN1A—esophageal cancer	3.61e-07	3.78e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—GNG7—esophageal cancer	3.6e-07	3.77e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—TP53—esophageal cancer	3.57e-07	3.73e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—HMOX1—esophageal cancer	3.56e-07	3.73e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—PIK3CA—esophageal cancer	3.55e-07	3.72e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—PIK3CA—esophageal cancer	3.55e-07	3.72e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—PIK3CA—esophageal cancer	3.55e-07	3.72e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—TP53—esophageal cancer	3.54e-07	3.71e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—MYC—esophageal cancer	3.54e-07	3.71e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—PIK3CA—esophageal cancer	3.54e-07	3.71e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—MYC—esophageal cancer	3.53e-07	3.69e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—ERBB2—esophageal cancer	3.49e-07	3.65e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—EGFR—esophageal cancer	3.46e-07	3.63e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—PIK3CA—esophageal cancer	3.46e-07	3.62e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—PTGS2—esophageal cancer	3.46e-07	3.62e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—EGFR—esophageal cancer	3.45e-07	3.61e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—CCND1—esophageal cancer	3.44e-07	3.61e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—EP300—esophageal cancer	3.44e-07	3.61e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—TP53—esophageal cancer	3.44e-07	3.6e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—TP53—esophageal cancer	3.44e-07	3.6e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—EP300—esophageal cancer	3.43e-07	3.6e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—PTGS2—esophageal cancer	3.43e-07	3.59e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—PIK3CA—esophageal cancer	3.41e-07	3.57e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—PIK3CA—esophageal cancer	3.39e-07	3.55e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ALDH2—esophageal cancer	3.37e-07	3.53e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CCND1—esophageal cancer	3.36e-07	3.52e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—MYC—esophageal cancer	3.36e-07	3.52e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—PIK3CA—esophageal cancer	3.35e-07	3.51e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—TP53—esophageal cancer	3.35e-07	3.51e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—CDKN1A—esophageal cancer	3.33e-07	3.49e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—EGFR—esophageal cancer	3.28e-07	3.44e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—PIK3CA—esophageal cancer	3.27e-07	3.42e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—MYC—esophageal cancer	3.26e-07	3.41e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CDKN1A—esophageal cancer	3.25e-07	3.4e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—PIK3CA—esophageal cancer	3.24e-07	3.4e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CCND1—esophageal cancer	3.24e-07	3.39e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CCND1—esophageal cancer	3.22e-07	3.37e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—MYC—esophageal cancer	3.22e-07	3.37e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—GSTT1—esophageal cancer	3.21e-07	3.36e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—EGFR—esophageal cancer	3.19e-07	3.34e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CYP2A6—esophageal cancer	3.17e-07	3.32e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—EP300—esophageal cancer	3.17e-07	3.32e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—MYC—esophageal cancer	3.16e-07	3.31e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—MYC—esophageal cancer	3.16e-07	3.31e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—PIK3CA—esophageal cancer	3.15e-07	3.3e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—EGFR—esophageal cancer	3.15e-07	3.3e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CDKN1A—esophageal cancer	3.13e-07	3.28e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—PIK3CA—esophageal cancer	3.13e-07	3.28e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CDKN1A—esophageal cancer	3.12e-07	3.26e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—EP300—esophageal cancer	3.09e-07	3.24e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—EGFR—esophageal cancer	3.09e-07	3.24e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—EGFR—esophageal cancer	3.09e-07	3.24e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CCND1—esophageal cancer	3.08e-07	3.22e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—CREBBP—esophageal cancer	3.03e-07	3.17e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ENO1—esophageal cancer	3.01e-07	3.15e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PTGS1—esophageal cancer	3.01e-07	3.15e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—PIK3CA—esophageal cancer	3.01e-07	3.15e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—MYC—esophageal cancer	3e-07	3.14e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—PIK3CA—esophageal cancer	2.99e-07	3.14e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—MYC—esophageal cancer	2.99e-07	3.13e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—EP300—esophageal cancer	2.98e-07	3.12e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CDKN1A—esophageal cancer	2.98e-07	3.12e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—EP300—esophageal cancer	2.97e-07	3.11e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PSME1—esophageal cancer	2.96e-07	3.1e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PSME2—esophageal cancer	2.96e-07	3.1e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—EGFR—esophageal cancer	2.93e-07	3.07e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—EGFR—esophageal cancer	2.93e-07	3.06e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—TP53—esophageal cancer	2.91e-07	3.04e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—EP300—esophageal cancer	2.88e-07	3.01e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—EP300—esophageal cancer	2.85e-07	2.99e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—PIK3CA—esophageal cancer	2.85e-07	2.98e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—EP300—esophageal cancer	2.83e-07	2.97e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—PIK3CA—esophageal cancer	2.77e-07	2.9e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MYC—esophageal cancer	2.76e-07	2.89e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—TP53—esophageal cancer	2.76e-07	2.89e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—PIK3CA—esophageal cancer	2.73e-07	2.86e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—NOS3—esophageal cancer	2.71e-07	2.84e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—EGFR—esophageal cancer	2.7e-07	2.83e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MYC—esophageal cancer	2.7e-07	2.82e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—PIK3CA—esophageal cancer	2.68e-07	2.81e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—PIK3CA—esophageal cancer	2.68e-07	2.81e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—TP53—esophageal cancer	2.68e-07	2.8e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—TP53—esophageal cancer	2.64e-07	2.77e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—EGFR—esophageal cancer	2.64e-07	2.76e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MYC—esophageal cancer	2.6e-07	2.72e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—TP53—esophageal cancer	2.6e-07	2.72e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—TP53—esophageal cancer	2.6e-07	2.72e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MYC—esophageal cancer	2.58e-07	2.71e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CYP1B1—esophageal cancer	2.56e-07	2.68e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—PIK3CA—esophageal cancer	2.55e-07	2.67e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—EGFR—esophageal cancer	2.54e-07	2.66e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—PIK3CA—esophageal cancer	2.54e-07	2.66e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—EGFR—esophageal cancer	2.53e-07	2.65e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PTGS2—esophageal cancer	2.48e-07	2.59e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MYC—esophageal cancer	2.47e-07	2.59e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—TP53—esophageal cancer	2.46e-07	2.58e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—TP53—esophageal cancer	2.46e-07	2.57e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—EGFR—esophageal cancer	2.42e-07	2.53e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CYP19A1—esophageal cancer	2.4e-07	2.52e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—PIK3CA—esophageal cancer	2.35e-07	2.46e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—PIK3CA—esophageal cancer	2.29e-07	2.4e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—CREBBP—esophageal cancer	2.28e-07	2.39e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—TP53—esophageal cancer	2.27e-07	2.38e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—TP53—esophageal cancer	2.21e-07	2.32e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—PIK3CA—esophageal cancer	2.21e-07	2.31e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—PIK3CA—esophageal cancer	2.19e-07	2.3e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—HMOX1—esophageal cancer	2.19e-07	2.3e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—TP53—esophageal cancer	2.13e-07	2.23e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—PIK3CA—esophageal cancer	2.13e-07	2.23e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—TP53—esophageal cancer	2.12e-07	2.22e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—PIK3CA—esophageal cancer	2.11e-07	2.21e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ABCB1—esophageal cancer	2.11e-07	2.2e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—PIK3CA—esophageal cancer	2.1e-07	2.2e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—EP300—esophageal cancer	2.06e-07	2.16e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—NOS3—esophageal cancer	2.04e-07	2.14e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—TP53—esophageal cancer	2.03e-07	2.12e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PTGS2—esophageal cancer	1.87e-07	1.96e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—EP300—esophageal cancer	1.56e-07	1.63e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PIK3CA—esophageal cancer	1.52e-07	1.6e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CREBBP—esophageal cancer	1.41e-07	1.47e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—NOS3—esophageal cancer	1.26e-07	1.32e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PTGS2—esophageal cancer	1.15e-07	1.21e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PIK3CA—esophageal cancer	1.15e-07	1.2e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—EP300—esophageal cancer	9.58e-08	1e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PIK3CA—esophageal cancer	7.09e-08	7.42e-07	CbGpPWpGaD
